Information
-
Trademark
-
97683391
-
International Classifications
-
Filing Date
November 18, 2022
a year ago
-
Transaction Date
July 18, 2024
a month ago
-
Status Date
July 17, 2024
a month ago
-
Location Date
July 17, 2024
a month ago
-
Status Code
616
-
Current Location
INTENT TO USE SECTION
Employee Name
TOOLEY, DAVID E
-
Attorney Docket Number
MLB-TM000400
Attorney Name
Don D. Cha
Law Office Assigned Location Code
N70
-
Owners
Mark Drawing Code
3
Mark Identification
MB MAINLINE BIOSCIENCES
Case File Statements
- DM0000: The mark consists of a stylized M to the left of a stylized B above the stylized wording MAINLINE BIOSCIENCE above the non-Latin characters that transliterate to MAIN SOURCE BIOTECHNOLOGY.
- AF0421: The mark was first used anywhere in a different form other than that sought to be registered at least as early as 01/01/2018
- TL0000: The non-Latin characters in the mark transliterate to ZHULIU YUAN SHENGWUKEJI and this means MAIN SOURCE BIOTECHNOLOGY in English.
- AF0422: The mark was first used in commerce in a different form other than that sought to be registered at least as early as 01/01/2018
- GS0051: Pharmaceutical preparations for the prevention of cancer or tumor; Pharmaceutical preparations for the treatment and prevention of cancer or tumor; Pharmaceutical preparations for the treatment of cancer or tumor; Pharmaceutical preparations for cancer or tumor; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer or tumor
- AF0052: The mark was first used in commerce in a different form other than that sought to be registered at least as early as 01/01/2018
- AF0051: The mark was first used anywhere in a different form other than that sought to be registered at least as early as 01/01/2018
- CC0000: Color is not claimed as a feature of the mark.
- DS0000: "BIOSCIENCES"
- GS0421: Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Development of pharmaceutical preparations and medicines; Laboratory research services relating to pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research on the subject of pharmaceuticals; Testing of pharmaceuticals
Case File Event Statements
-
12/10/2022 - a year ago
3 - NOTICE OF DESIGN SEARCH CODE E-MAILED
Type: MDSC
-
11/22/2022 - a year ago
1 - NEW APPLICATION ENTERED
Type: NWAP
-
12/9/2022 - a year ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Type: NWOS
-
8/30/2023 - a year ago
4 - ASSIGNED TO EXAMINER
Type: DOCK
-
9/1/2023 - a year ago
5 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
9/1/2023 - a year ago
6 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
9/1/2023 - a year ago
7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
12/1/2023 - 9 months ago
8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
12/1/2023 - 9 months ago
9 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
12/2/2023 - 9 months ago
10 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
4/11/2024 - 5 months ago
15 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Type: XELG
-
7/17/2024 - a month ago
16 - TEAS PETITION TO REVIVE RECEIVED
Type: PROA
-
7/17/2024 - a month ago
18 - NOTICE OF REVIVAL - E-MAILED
Type: NREV
-
7/17/2024 - a month ago
17 - PETITION TO REVIVE-GRANTED
Type: PETG
-
7/17/2024 - a month ago
19 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
1/11/2024 - 8 months ago
11 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
1/11/2024 - 8 months ago
12 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
1/11/2024 - 8 months ago
13 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
4/11/2024 - 5 months ago
14 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Type: XELR